Theratechnologies (TSE:TH) Sets New 52-Week High - Still a Buy?

Key Points

• Theratechnologies Inc. shares reached a new 52-week high of C$4.38 during trading, with recent trading volume reported at 11,926 shares.
• The company has been downgraded from a "strong-buy" to a "hold" rating by Jones Trading as of July 3rd.
• Theratechnologies specializes in addressing the medical needs of HIV patients, offering two approved products: EGRIFTA and Trogarzo.

Theratechnologies Inc. (TSE:TH - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$4.38 and last traded at C$4.38, with a volume of 11926 shares changing hands. The stock had previously closed at C$4.37.

Wall Street Analysts Forecast Growth

Separately, Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.

Theratechnologies Trading Down 0.5%

The firm's 50-day moving average is C$3.90 and its 200-day moving average is C$3.20. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of -293.92. The firm has a market cap of C$140.38 million, a price-to-earnings ratio of -49.81, a P/E/G ratio of -8.50 and a beta of 1.73.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.